JUL 24, 2019 10:40 PM PDT

HIV Therapeutics Places Risk of Neural Tube Defects

WRITTEN BY: Nouran Amin

In a study published in the New England Journal of Medicine, women taking an HIV therapeutic drug containing dolutegravir have a higher risk of giving birth to children with neural tube defects particularly in comparison to women taking other antiretroviral drug regimens.

Learn more on neural tube defects:

Neural tube defects consist of abnormalities in the development of the brain and spinal column. The NICHD-funded study, which began in 2014 in Botswana, was used to track birth outcomes, including neural tube defects for infants born to women taking antiretroviral therapy for an HIV infection in eight hospitals.

Upon findings, Botswana changed their treatment guidelines to recommend drug combinations containing dolutegravir for all adults, this included pregnant women. However, later preliminary studies indicated a potential risk between mothers receiving the drug and neural tube defects among their infants—this is especially true for women who received the dolutegravir treatment around the time they conceived.

During the International AIDS Society Conference, researchers reported their findings describing women that were on dolutegravir since conception. Of these women, five neural tube defects occurred out of 1,683 births (0.3%). However, women who were on the drug, efavirenz, since conception had three cases of neural tube defects out of 7,959 births (0.04%). Furthermore, women receiving another HIV treatment regimens that did not involve dolutegravir had 15 neural tube defect cases out of 14,792 births (0.1%). At the end, the findings concluded 0.2% difference in risk for infants born to women on dolutegravir drug therapy since conceiving. Although the risk is small, findings are significant.

Source: National Institute of Health

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 19, 2019
Drug Discovery & Development
SEP 19, 2019
Injectable Hydrogel Recruits Chemotherapeutics to Tumor Site
Targeting tumor cells while avoiding harming healthy tissue remains a growing central challenge in the field of chemotherapeutics. For a while, scientists ...
SEP 19, 2019
Drug Discovery & Development
SEP 19, 2019
Why Drugs that Work on Mice Don't Work on Humans
Mice are used as the frontline for drug testing for brain disorders. Why? Their brains are supposed to have much of the same functioning as ours. Moreover,...
SEP 19, 2019
Cell & Molecular Biology
SEP 19, 2019
How the Kava Plant Creates Medicinal Compounds
Nature has given us some of our best medicines; it's thought that as many as half the drugs we used are derived from natural products....
SEP 19, 2019
Drug Discovery & Development
SEP 19, 2019
Diabetic Drugs Offer Protection Against Kidney Failure
Kidney failure is a consequence of diabetic kidney disease--roughly 3 million people are seeking treatment worldwide for kidney failure and the numbers are...
SEP 19, 2019
Drug Discovery & Development
SEP 19, 2019
Does TruBrain Really Work?
TruBrain is a mix of different substances claimed to help people increase verbal fluency, avoid distractions, and boost their mental output. Created by a t...
SEP 19, 2019
Drug Discovery & Development
SEP 19, 2019
Transplanted Brain Stem Cells Survive Without Anti-Rejection Drugs
Researchers at Johns Hopkins Medicine have successfully transplanted brain cells without the need of immune-suppressing drugs. Findings of the study were p...
Loading Comments...